TY - JOUR
T1 - Mitigating the Risk
T2 - Transfusion or Reoperation for Bleeding After Cardiac Surgery
AU - Investigators for the Maryland Cardiac Surgery Quality Initiative
AU - Pasrija, Chetan
AU - Ghoreishi, Mehrdad
AU - Whitman, Glenn
AU - Ad, Niv
AU - Alejo, Diane E.
AU - Holmes, Sari D.
AU - Schena, Stefano
AU - Salenger, Rawn
AU - Mazzeffi, Michael A.
AU - Fonner, Clifford E.
AU - Taylor, Bradley
N1 - Funding Information:
Funding for this research was provided by the Maryland Cardiac Surgery Quality Initiative (MCSQI).
Publisher Copyright:
© 2020 The Society of Thoracic Surgeons
PY - 2020/8
Y1 - 2020/8
N2 - Background: Several studies have established morbidity associated with bleeding after cardiac surgery. Although reoperation has been implicated as the marker for this morbidity, there remains limited understanding regarding relative morbidities of reoperation and substantial transfusion. Methods: The Society of Thoracic Surgeons (STS) Maryland Adult Cardiac Surgery Database (July 2011-September 2018) was reviewed (N = 23,240). Substantial transfusion was defined as requiring greater than the reoperation group median red blood cells (5 units) and non-red blood cells (4 units). Patients were stratified into 4 subgroups: group 1, no reoperation without substantial transfusion (n = 22,365); group 2, reoperation without substantial transfusion (n = 351); group 3, no reoperation with substantial transfusion (n = 350); and group 4, reoperation with substantial transfusion (n = 167). Operative morbidity and mortality were compared. Results: Reoperation patients were older with a higher STS predicted risk of mortality (1.8% vs 1.2%, P < .001). Multivariable analysis demonstrated that group 4 increased the odds of renal failure (odds ratio [OR] 7.36, P < .001), stroke (OR 3.24, P = .002), and operative mortality (OR 8.68, P < .001) compared with group 1. Both group 2 and group 3 increased the odds of mortality and renal failure compared with group 1. However, group 3 had greater risk for renal failure (OR 3.48, P < .001) and mortality (OR 2.91, P < .001) than group 2. Conclusions: Although reoperation for bleeding is associated with morbidity after cardiac surgery, substantial transfusion without reoperation appears to increase morbidity compared with a limited-transfusion reoperative approach. Better timing for reoperation and guided transfusion approaches may mitigate morbidity compared with substantial transfusion alone.
AB - Background: Several studies have established morbidity associated with bleeding after cardiac surgery. Although reoperation has been implicated as the marker for this morbidity, there remains limited understanding regarding relative morbidities of reoperation and substantial transfusion. Methods: The Society of Thoracic Surgeons (STS) Maryland Adult Cardiac Surgery Database (July 2011-September 2018) was reviewed (N = 23,240). Substantial transfusion was defined as requiring greater than the reoperation group median red blood cells (5 units) and non-red blood cells (4 units). Patients were stratified into 4 subgroups: group 1, no reoperation without substantial transfusion (n = 22,365); group 2, reoperation without substantial transfusion (n = 351); group 3, no reoperation with substantial transfusion (n = 350); and group 4, reoperation with substantial transfusion (n = 167). Operative morbidity and mortality were compared. Results: Reoperation patients were older with a higher STS predicted risk of mortality (1.8% vs 1.2%, P < .001). Multivariable analysis demonstrated that group 4 increased the odds of renal failure (odds ratio [OR] 7.36, P < .001), stroke (OR 3.24, P = .002), and operative mortality (OR 8.68, P < .001) compared with group 1. Both group 2 and group 3 increased the odds of mortality and renal failure compared with group 1. However, group 3 had greater risk for renal failure (OR 3.48, P < .001) and mortality (OR 2.91, P < .001) than group 2. Conclusions: Although reoperation for bleeding is associated with morbidity after cardiac surgery, substantial transfusion without reoperation appears to increase morbidity compared with a limited-transfusion reoperative approach. Better timing for reoperation and guided transfusion approaches may mitigate morbidity compared with substantial transfusion alone.
UR - http://www.scopus.com/inward/record.url?scp=85083744210&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083744210&partnerID=8YFLogxK
U2 - 10.1016/j.athoracsur.2019.10.076
DO - 10.1016/j.athoracsur.2019.10.076
M3 - Article
C2 - 31866482
AN - SCOPUS:85083744210
SN - 0003-4975
VL - 110
SP - 457
EP - 463
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 2
ER -